Jefferies Group's AXSM Position Overview
Jefferies Group (via Jefferies Financial Group Inc.) currently holds 15,500 shares of Axsome Therapeutics, Inc. (AXSM) worth $2.62 M, representing 0.02% of the portfolio. First purchased in 2023-Q3, this medium-term investment has been held for 10 quarters.
Based on 13F filings, Jefferies Group has maintained a strategic position in AXSM, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2024, adding 40,700 shares. Largest reduction occurred in Q2 2024, reducing 316,907 shares.
Analysis based on 13F filings available since 2013 Q2
Jefferies Group's Axsome Therapeutics (AXSM) Holding Value Over Time
Track share changes against reported price movement
Quarterly Axsome Therapeutics (AXSM) Trades by Jefferies Group
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +15,500 | New Buy | 15,500 | $169.02 |
| Q3 2025 | -2,500 | Sold Out | 0 | $0.00 |
| Q2 2025 | +2,500 | New Buy | 2,500 | $104.39 |
| Q1 2025 | -40,700 | Sold Out | 0 | $0.00 |
| Q4 2024 | +40,700 | New Buy | 40,700 | $84.61 |
| Q3 2024 | -15,859 | Sold Out | 0 | $0.00 |
| Q2 2024 | -316,907 | Reduce 95.23% | 15,859 | $80.50 |
| Q1 2024 | -230,569 | Reduce 40.93% | 332,766 | $79.80 |
| Q4 2023 | +10,140 | Add 1.83% | 563,335 | $79.59 |
| Q3 2023 | +553,195 | New Buy | 553,195 | $69.89 |
Jefferies Group's Axsome Therapeutics Investment FAQs
Jefferies Group first purchased Axsome Therapeutics, Inc. (AXSM) in Q3 2023, acquiring 553,195 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jefferies Group has held Axsome Therapeutics, Inc. (AXSM) for 10 quarters since Q3 2023.
Jefferies Group's largest addition to Axsome Therapeutics, Inc. (AXSM) was in Q3 2023, adding 553,195 shares worth $38.66 M.
According to the latest 13F filing for Q1 2026, Jefferies Group's firm, Jefferies Financial Group Inc., owns 15,500 shares of Axsome Therapeutics, Inc. (AXSM), valued at approximately $2.62 M.
As of the Q1 2026 filing, Axsome Therapeutics, Inc. (AXSM) represents approximately 0.02% of Jefferies Group's publicly disclosed stock portfolio, making it one of their key holdings.
Jefferies Group's peak holding in Axsome Therapeutics, Inc. (AXSM) was 563,335 shares, as reported at the end of Q4 2023.